Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults with Prediabetes: systematic review and meta-analysis of randomized controlled trials.
Yuichiro MoriO Kenrik DuruKatherine R TuttleShingo FukumaDaisuke TauraNorio HaradaNobuya InagakiKosuke InouePublished in: The Journal of clinical endocrinology and metabolism (2022)
In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of new-onset type 2 diabetes among adults with prediabetes and heart failure or chronic kidney disease. These findings indicate the potential usefulness of SGLT2 inhibitors in preventing diabetes among high-risk populations with prediabetes.